The newly launched tools aim to reduce the time and costs of marketing new drugs by "debugging" the lab environment.
Social listening can help all along the value chain—from research and discovery to developing marketing plans and strategy.
Despite conventional wisdom that the 23andMe business breakthrough is the direct-to-consumer model, it's also the consolidation of genetic testing, diagnosis and drug development that has the potential to change the industry.
Healthcare spending rose in 2014; Publicis reorganizes its agency network; proposed New Jersey bill would punish drugmakers that move abroad
Healthcare may seem to have been unscarred by the ongoing rash of high-profile cyber-attacks, at least compared with retail and financial organizations. But to hear security pros tell it, the industry is increasingly finding itself as much of a target as companies in other sectors—if not more of one. Karen Epper Hoffman surveys the potential damage
Specialty medicines will keep drug spend trending upward through the next five years.
If more physicians begin participating in late-phase research efforts—and work to educate patients about these opportunities—we can expect new innovations in treatment solutions to come more quickly to market.
Soon, IBM says, Watson will be used by one particular pharma company to create a website where, once a drug is prescribed, patients can ask questions in their own words and the website will provide answers in near real-time.
A pair of surveys paint a complicated picture of what direction pharma access to healthcare providers is going.
The public said drugmakers spend too much money on marketing to doctors and patients
Initiatives in Europe follow the US example when it comes to requiring manufacturers to report information about financial relationships with physicians.
As pharma marketers continue on their age-old quest to engage physicians, the either/or choice between reps and digital tactics has largely gone away in favor of programs that incorporate both. At the same time, certain segments of the business are still finding their way in the brave new digital world. Larry Dobrow surveys the scene
Programmatic buying has started to take over the placement of digital ads, to the tune of $15 billion in 2015 sales. Is pharma in the process of following suit or will concerns about privacy and fraud dampen industry enthusiasm? Barbara Peck assesses the pros and cons
Amgen reportedly asks Repatha patients seeking financial assistance for personal health information; Valeant faces more scrutiny of business model; the FDA approves new J&J cancer drug
Sanofi's Aubagio reduces brain volume loss; cancer specialists avoid pricey cancer meds; analysis says placebo effect is on the rise
By equipping patients with biosensors, wearable devices and mobile apps, clinical R&D teams have the opportunity to gain unprecedented insight about the patient experience.
The firm is the primary vendor for the drugmaker's global commercial analytics.
An analysis of R&D data from 14 large drugmakers found that pharma is having renewed success in bringing medicines to market.
Report finds Americans overpay for cancer drugs; Clinton proposes end to pharma DTC as a tax write-off; Gilead HCV combo is effective across all strains of the virus
Accenture found that life-sciences executives believe that smart tools and devices will be the catalyst for drugmakers to move forward with beyond-the-pill initiatives.
As the value proposition of real-world data to drugmakers becomes increasingly attractive, services companies are partnering to capitalize on the opportunity.
Cardiologists say that up to 15% of their patients could be on PCSK9 inhibitors next year; FDA committee to evaluate new Oxycodone version
Sales reps that focus on creating value for HCPs could find new opportunities and improved access to those physicians, according to Accenture.
The cloud technology firm announced it will acquire Avalere in a move aimed at growing its relationships with pharma.
A new poll conducted by the Kaiser Family Foundation found that most Americans believe drugmakers should be required to release information to the public about how they set drug prices.
Less than half of 300 doctors polled in a QuantiaMD survey could name a biosimilar that's under consideration for approval, and only 17% said they're very likely to prescribe one.
The focus on boosting physician referrals might appear contrary to the current obsession with patient-centric marketing.
The National Organization for Rare Disorders and the University of Maryland will develop a training program to help caregivers and patients participate in research.
Adults dominate the ADHD prescription category; the FDA approved The Medicine Company's anticlotting drug 10 years after issuing a CRL; a survey shows personalized content can build consumer goodwill
A data-mining analysis of patient records found a significant increase in the chance of heart attack for those taking proton-pump inhibitors.
The academic partnership builds on the company's 2014 collaboration with UCB on using sensors to gather biometric data about people with neurological disorders.
He spoke with MM&M about whether pharma is ready to win a Grand Prix, if regulation limits creativity in healthcare, and why wearables may spur creativity.
A Pfizer poll shows patients rely on over-the-counter medications but need help finding the right treatment.
The drugmaker and patient network teamed up to establish a formal framework for deploying activity trackers for patients with MS and for capturing that data.
IBM takes on healthcare data; Mylan settled a lawsuit allowing it to launch generic Viagra by 2017; an FDA committee will meet today to discuss Onglyza
The American Academy of Otolaryngology said taking antibiotics for sinus infections is a slightly better treatment strategy than waiting it out.
A new survey from Cegedim Relationship Management claims that digital tools are being underutilized and represent an opportunity to meet the demands of HCPs.
A small physician survey shows doctors think their patients have higher adherence rates than the norm.
A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.
"Although the United States represents almost half of the biologics market in terms of revenue and volume, biosimilars growth will be fueled by focusing on the emerging markets, by addressing non-consumption and patient inability to pay for high-priced biologics."
Members of the 13-32 age group were less likely to agree that preventive care is the most important factor in staying healthy, compared to Baby Boomers and Gen-Xers.
As patients spend more time in waiting rooms where they are primed to learn about their health, POC promotions are becoming a more essential part of the marketing mix, researchers find.
Complementary solutions to drive growth with health plans as well as pharma clients, companies say.
Despite hurdles of practitioner buy-in and legacy IT, value-based care is on pace to overtake fee-for-service.
An arduous reimbursement process has put a damper on how quickly patients can receive the drug, say analysts, citing KOLs.
Life expectancy for patients cured of advanced HCV similar to healthy peers: study; Ackman takes a $2 billion stake in animal drugmaker Zoetis; Amgen and AstraZeneca report that brodalumab bested Stelara in psoriasis head-to-head.
The CBO projected 13 million enrolled in 2015, but its projections were based before final 2014 numbers were in.
FDA will evaluate effect of pharma commercial barrage; Pfizer settles Neurontin marketing lawsuit for $321 million; AbbVie and Gilead release top-line results on HCV combo therapies.
Developing exclusive features from proven generics is a growing opportunity for patients as much as it is a ploy for life-cycle extension.
An FDA study of Medicare patients found that patients who took Pradaxa showed a reduced risk of stroke and brain hemorrhage.
According to a survey, general practitioners are against new NHS guidelines on prescribing statins.
Orphan drug growth will easily outpace non-orphans through 2020.
In a study to observe their effect in DTC ads, comparison claims in both print and video ads led consumers to trust those drugs over rival medications, researchers found.
Researchers conclude that "more prominent warnings" are warranted for the class known as dopamine receptor agonists.
There are similarities between the 2014 formularies and their commercial counterparts. However, differences in the drug benefit designs show the predominance of four to five tiers, higher deductibles and higher copays or coinsurance levels compared to commercial benefits.
A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.
Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.
Healthcare workers seek out health-related information on their own time, and through internet connections other than ones offered by their employers.
The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.
The latest data shows an overall widening of the US.
The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.
Tech site Venturebeat, citing anonymous sources, says doctors are too overwhelmed and weary to evaluate how many steps you took this weekend.
African-American women had the highest risk of being diagnosed with diabetes—55%. Hispanic men and women were close behind, carrying a 50% risk of being diagnosed with diabetes.
A study indicates consumers stop using them at the six-month mark.
Half-measures, like diabetes educational materials without a part B, fared poorly.
The pharma payment verification site has been temporarily shut down by CMS due to incorrect information, ProPublica reported today.
A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.
Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like meals, travel, gifts, consulting and research
Generics made up almost 75% of prescriptions in the United Kingdom last year.
The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.
An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.
The rate of decrease in industry's budget for continuing medical education (CME) slowed last year.
Industry reined in commercial support for CME in 2013—the sixth consecutive annual decrease—data released today by the ACCME show.
German healthcare data from 2004 through 2010 across a data set that included 146,000 patients shows dementia surfaced later among Actos patients.
The FDA began its drug review at a median time of 103 days sooner than the EMA. Being first, researchers found, often resulted in quicker approval.
Prices for some generics are rising, thanks to limited competition.
Credit card and loyalty program purchases will help Carolinas HealthCare System flag potential patient behavior issues.
Zogenix is working on a less easily abused formulation of its controversial prescription painkiller.
The Centers of Disease Control reports that prescribers wrote enough painkiller prescriptions to give one bottle to every adult in the US in 2012.
The networking site's emotion experiment rankles some in the science and political communities.
IMS is offering $520 million cash to add Cegedim's CRM and strategic data business. Cegedim says it will use the money to pay down debt.
EvaluatePharma's World Preview 2014 has pharma soaring to new lucrative heights in six years' time, buoyed by biologics and a formidable pipeline.
Phase III results showing improved lung function among cystic fibrosis patients using a combination of Kalydeco and lumacaftor means drugmaker Vertex is filing the two-part drug for FDA approval during the fourth quarter.
Platform lets pharma firms mine big data, and monitor whether millions spent on ad campaigns or medical education are having the desired effect
Gene mutations lead researchers to rethink ways to protect the heart.
An Alzheimer's Association survey finds 59% think the degenerative disease is just part of aging.
Researchers at Montreal's McGill University survey the explosion in prescription painkiller use and abuse.
The drugmaker has told global regulators it failed to share 10,000 reported cases of side effects for a variety of its drugs.
Patients taking a high-dose form of Novo Nordisk diabetes drug Victoza saw an average weight loss of 5.9% of their body weight, data from a study show.
A USA today analysis shows Medicare painkiller prescriptions rose 30% between 2007 and 2012.
Yale researchers find patients are paying more money for newer diabetes medications as they gravitate towards insulin analogs, over human synthetic and animal insulin.
Researchers argue it makes economic sense to employ Value-Based Insurance Design plans for costly specialty medications.
Two studies found two different facets of statin therapy—one found patients moved less a year after starting their regimens, and another that the drugs upped the diabetes risk for some.
Express Scripts said that family and internal medicine doctors were the top opioid prescribers between 2011 and 2012.
A study shows doctors have been giving more political donations—and leaning heavily Democrat—since 1991.
Researchers say switching patients from Lucentis to Avastin eye diseases could save the government $18 billion.
The potential of immunotherapy is great, but the news from the 2014 medical meeting shows that great may not be gargantuan in terms of treatment reach.
The regulator's latest study will use eye-tracking tools.
The regulator is allocating almost $38 million to improve data-guided decision-making.
The pharma market research major is working on unifying into one company with two main product lines, and is also in the process of a re-brand.